This creates an increased ratio of kynurenine to tryptophan, which is proposed to contribute to an immunosuppressive tumour microenvironment, in part (but not entirely) through activity of kynurenine on the aryl hydrocarbon receptor (AhR) [27, 28]. The gene discussed is AHR; the disease is neoplasm.